Institute for Protein Design

What Institute for Protein Design does

The Institute for Protein Design (IPD) is a research institute within the University of Washington School of Medicine in Seattle, founded in 2012, that develops AI-powered computational methods for de novo protein design. Its core technology stack includes the RFdiffusion3 foundation model (an open-source generative AI system for designing proteins that interact with DNA, small molecules, and other cellular targets), ProteinMPNN (a deep learning sequence-design method achieving 52.4% recovery on native backbones versus 32.9% for legacy Rosetta), and the Rosetta software suite. The institute's platform has been validated through SKYCovione, the world's first computationally designed protein medicine to achieve regulatory approval (WHO Emergency Use Listing, plus UK and South Korea approvals), and is being expanded into oncology (via the incoming Dr. Green Ahn faculty hire), universal coronavirus vaccines (GBP511 in Phase 1/2 trials), and tuberculosis diagnostics (via Monod Bio).

IPD operates an academic-style, grant-and-licensing revenue model rather than direct product sales. Funding is sourced from federal and private research grants (NIH, CEPI ~$65M for GBP511, Gates Foundation, Washington Research Foundation $7M four-year grant, The Audacious Project $45M), case-by-case technology licensing to pharmaceutical and biotechnology companies, and equity stakes in a portfolio of six spinout companies (Icosavax, Neoleukin Therapeutics, Monod Bio, Arzeda, Cyrus Biotechnology, and PvP Biologics, which was acquired by Takeda). The institute does not disclose revenue separately, and SKYCovione technology was licensed royalty-free during the COVID-19 pandemic.

The institute serves pharmaceutical companies (Takeda, SK bioscience), biotechnology spinouts and partners (Xaira Therapeutics, Neoleukin), global health organizations (CEPI, WHO, Gates Foundation), and academic research institutions worldwide. Distribution is conducted through technology licensing, open-source software distribution via Rosetta Commons, spinout company formation, and collaborative research partnerships with industry.

Name

Institute for Protein Design

Legal name

Institute for Protein Design at University of Washington School of Medicine

Website

https://ipd.uw.edu

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

The Institute for Protein Design is an academic research unit at the University of Washington School of Medicine that pioneers AI-driven computational protein design for therapeutics, vaccines, and sustainable materials, licensing technology to pharmaceutical partners and spinning out biotech companies.

Ownership category

akta.pro rank

Product category

Computational Biology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Patent Owners & Lessors (6794)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Computational protein design
• AI protein engineering
• Biomolecular modeling software
• Protein therapeutics research
• Nanoparticle vaccine platform

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Technology Licensing: Licensing of protein design technologies and IP to pharmaceutical and biotechnology companies. The COVID-19 vaccine SKYCovione technology was licensed royalty-free for the duration of the pandemic. Ongoing licensing of nanoparticle vaccine platform and other technologies.
2. Research Funding and Grants: Federal and private research grants supporting academic research programs. Major funders include NIH, CEPI, Gates Foundation, Washington Research Foundation, and The Audacious Project.
3. Spinout Company Equity: Revenue generated through equity stakes in spinout companies including Icosavax, Neoleukin Therapeutics, PvP Biologics (acquired by Takeda), Arzeda, Cyrus Biotechnology, and Monod Bio.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

The Institute for Protein Design (IPD) is a research institute at the University of Washington School of Medicine that computationally designs novel proteins from scratch using AI/machine learning methods. It develops and distributes open-source protein design software (RFdiffusion3, Rosetta, ProteinMPNN) and licenses its protein engineering technologies and intellectual property to pharmaceutical and biotechnology companies through university technology transfer and spinout companies. Its work has produced the world's first computationally designed protein medicine (SKYCovione COVID-19 vaccine) to achieve regulatory approval.

Differentiator

Problem solved

Functional benefit

Brands

• RFdiffusion3: State-of-the-art open-source AI model for biodesign capable of generating proteins that interact with DNA and small molecules
• SKYCovione
• GBP511
• Baker Lab
• King Lab
• FluMos-v2
• Icosavax
• Neoleukin Therapeutics
• Monod Bio

Products and services

• RFdiffusion3 Open-source AI foundation model for de novo protein design, generating novel proteins that interact with DNA, small molecules, and other biomolecules using atom-level diffusion modeling. Released on GitHub for the scientific community.
• Rosetta Software Suite

Quantifiable outcome

• SKYCovione elicits approximately 3 times more neutralizing antibodies than Oxford/AstraZeneca vaccine in Phase 3 trials
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core, flagship and minor.

• NVIDIAcoreTechnology or Integration · 23 June 2026NVIDIA BioNeMo Agent Toolkit integration with IPD technologies. University of Washington's Institute for Protein Design reported 2x faster performance on state-of-the-art biodesign models using NVIDIA's life sciences AI tools.
• SK bioscienceflagshipStrategic or Co-development Partner · 29 January 2026South Korean pharmaceutical company leading clinical development of GBP511 universal sarbecovirus vaccine and SKYCovione COVID-19 vaccine using IPD's nanoparticle platform. Phase 1/2 trial initiated January 2026 with approximately 368 adults in Australia. SKYCovione received regulatory approval in UK and South Korea.
• Xaira TherapeuticsflagshipStrategic or Co-development Partner · 5 November 2025Biotechnology company launched April 2024 with $1 billion in capital, expanding RFdiffusion technology for drug development. Has assembled leadership team including Nobel Laureates and former industry executives. Licensed IPD technology for AI-designed antibody development.
• BioInnovation Institute (BII)minorStrategic or Co-development Partner · 5 January 2023International enterprise foundation incubating life science research accepted IPD's first international translational research project into its Bio Studio program based on AI and protein design breakthroughs.
• Monod BiocoreStrategic or Co-development Partner · 15 August 2022IPD spinout developing custom diagnostic biosensors that emit light to detect specific biomolecules. Raised $25 million seed financing led by Matrix Capital with participation from Gates Foundation and others.
• GlaxoSmithKlinecoreStrategic or Co-development Partner · 29 June 2022GSK provided pandemic adjuvant AS03 for SKYCovione COVID-19 vaccine development, working with SK bioscience and IPD researchers.
• Takeda PharmaceuticalsflagshipOEM/ Whitelabel/ Licensing Partner · 26 February 2020Takeda acquired PvP Biologics (IPD spinout) and is advancing TAK-062 (KumaMax) enzyme for celiac disease treatment in the clinic. Original agreement valued at $35 million plus acquisition option.
• Neoleukin TherapeuticscoreStrategic or Co-development Partner · 8 August 2019IPD spinout developing Rosetta-designed protein platform for cancer, inflammation, and autoimmune diseases. Merged with Aquinox Pharmaceuticals and went public within 7 months of spinout.
• IcosavaxcoreStrategic or Co-development Partner · 3 October 2017IPD spinout company developing nanoparticle vaccines for infectious disease including RSV vaccine candidate. Founded on computationally designed self-assembling VLP technology developed at IPD. Series A financing of $51 million.
• ArzedacoreStrategic or Co-development Partner · 17 November 2016IPD spinout commercializing Rosetta-based computational enzyme design technology. Raised $12 million Series A and established partnerships with Amyris and DARPA for sustainable molecule development.
• Cyrus BiotechnologycoreStrategic or Co-development Partner · 1 October 2015First IPD spinout company commercializing Cyrus Bench software based on Rosetta technology. Raised $8 million Series A financing from Trinity Ventures, OrbiMed Advisors, and others.

Scale indicators8 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Generate Biomedicines: Flagship AI-driven generative biology company developing de novo protein therapeutics using foundation models. Directly comparable to IPD in that it builds generative AI for protein design and partners with major pharma (e.g., Amgen), competing for the same talent and partnership pipeline.
• Isomorphic Labs: Alphabet-backed commercial spinout of DeepMind applying AlphaFold technology to drug discovery and protein design. The most well-capitalized direct competitor to IPD's AI protein design platform, targeting pharma partnerships across therapeutic discovery.
• Xaira Therapeutics: AI-driven drug discovery company that launched in April 2024 with $1B in capital, explicitly licensing IPD's RFdiffusion technology for antibody design. Competes head-to-head for AI-designed antibody programs and pharma partnerships originating from IPD's platform.

Emerging players

• Cradle Biosciences: AI protein engineering company focused on designing improved proteins for therapeutics, diagnostics, and industrial applications. Comparable to IPD in its generative approach to protein design and target use cases across pharma and biotech.
• Arzeda: IPD spinout commercializing Rosetta-based computational enzyme design for industrial biotech and sustainable molecules. Comparable as a direct spinout of the same IPD technology stack, applying it to enzyme and protein engineering.
• Monod Bio: IPD spinout developing AI-designed diagnostic biosensors using custom protein binders. Comparable as a direct spinout of the same Baker Lab protein design platform, applying de novo binders to point-of-care diagnostics.
• Cyrus Biotechnology: First IPD spinout commercializing the Rosetta protein modeling software through the Cyrus Bench platform. Comparable as the original spinout of IPD's core Rosetta software technology, serving protein engineering customers across biotech and pharma.

Broad incumbents

• Schrödinger, Inc. Public computational chemistry and biology platform providing physics-based and AI tools for molecular design and drug discovery. Comparable as a commercial computational biology platform serving pharma, though broader and more chemistry-focused than IPD's protein-centric stack.
• Insitro: AI-driven drug discovery company combining ML with high-throughput biology for therapeutic development. Comparable as a well-funded AI-bio platform building generative models for drug discovery, though focused more on target identification than protein design.
• Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput experimentation with ML models across multiple therapeutic areas. A broader AI-bio incumbent with comparable scale, capital, and ambition in computational drug discovery.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@UWproteindesign
• LinkedInlinkedin.com/company/uwproteindesign
• Xx.com/uwproteindesign
• Facebookfacebook.com/UWproteindesign

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries6 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institute for Protein Design